High Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Ex vivo Metabolic Studies of a Rhenium-Labeled Radiopharmaceutical for Liver Cancer

Abstract

The radio-isotope rhenium-labeled N-[2-(triphenylmethyl)thioethyl]-3-aza-19-ethyloxycarbonyl-3-[2-(triphenylmethyl)thioethyl] octadecanoate) ligand (¹⁸⁸Re-MN-16ET) is a novel therapeutic agent under preclinical evaluation for hepatoma. A reversed-phase high performance liquid chromatography coupled with a tandem mass spectrometric analysis method and diode array detector (DAD) involving a T type splitter was developed to characterize this pharmaceutical in rat liver tissue solution and determine its biotransformation rate. The separation was accomplished on a C18 column (chromolith silica, 4.6 mm × 100 mm) using an acetonitrile–ammonium acetate buffer gradient as the mobile phase. The detection was achieved by DAD set at 250 nm and tandem mass spectrometry using electrospray ionization in the positive ion mode. Re-MN-16ET displayed a retention time of 23.2 min and a transition ion pair corresponding to m/z 677 → 631 for multiple reaction monitoring. Its biotransformation reaction in rat liver homogenate proceeded for 90 min in a 37°C water bath. The characterization was conducted using aliquots that were extracted and concentrated from the reaction mixture for various incubation times. Re-MN-16ET exhibited a biotransformation half-life (t_1/2) of 8–9 min in liver tissue solution and was almost completely exhausted after 90 min. Two of its metabolites, consisting of the Re-labeled carboxylic acid derivative, predominately, and its corresponding demetallized disulfide ligand were found in the liver homogenate, providing a metabolism pathway for the radiopharmaceutical.

Keywords

Re-MN-16ET rat liver homogenate radio-transcatheter arterial embolization

Get full access to this article

View all access options for this article.

References

Befeler

A.S.

Di Bisceglie

A.M.

, “Hepatocellular carcinoma: Diagnosis and treatment”, Gastroenterology 122, 1609 (2002). doi: https://dx-doi-org.web.bisu.edu.cn/10.1053/gast.2002.33411

Liu

C.H.

Tsai

C.C.

Chen

H.H.

, “The diagnosis and treatment strategy of hepatocellular carcinoma”, J. Intern. Med. Taiwan 24, 85 (2013).

Wang

S.J.

Lin

W.Y.

Chen

M.N.

Hsieh

B.T.

Shen

L.H.

Tsai

Z.T.

Ting

Knapp

F.F.

Jr , “Biodistribution of rhenium-188 lipiodol infused via the hepatic artery of rats with hepatic tumors”, Eur. J. Nucl. Med. 23, 13 (1996). doi: https://dx-doi-org.web.bisu.edu.cn/10.1007/BF01736984

Kanematsu

Inokuchi

Sugimachi

Furuta

Sonoda

Tamura

Hasuo

, “Selective effects of lipiodolized antitumor agents”, J. Surg. Oncol. 25, 218 (1984). doi: https://dx-doi-org.web.bisu.edu.cn/10.1002/jso.2930250317

Ahmadzadehfar

Sabet

Wilhelm

Biersack

H.J.

Risse

, “Iodine-131-lipiodol therapy in hepatic tumours”, Methods 55, 246 (2011). doi: https://dx-doi-org.web.bisu.edu.cn/10.1016/j.ymeth.2011.05.003

Yoo

H.S.

Park

C.H.

Suh

J.H.

Lee

J.T.

Kim

D.I.

Kim

B.S.

Madsen

M.T.

, “Radioiodinated fatty acid esters in the management of hepatocellular carcinoma: Preliminary findings”, Cancer Chemother. Pharmacol. 23, 54 (1989). doi: https://dx-doi-org.web.bisu.edu.cn/10.1007/BF00647241

Luo

T.Y.

Hsieh

B.T.

Wang

S.J.

Lin

W.Y.

Lee

T.W.

Shen

L.H.

M.J.

, “Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection”, Nucl. Med. Biol. 31, 671 (2004). doi: https://dx-doi-org.web.bisu.edu.cn/10.1016/j.nucmedbio.2004.02.005

Lee

Y.S.

Jeong

J.M.

Kim

Y.J.

Chung

J.W.

Park

J.H.

Suh

Y.G.

Lee

D.S.

Chung

J.K.

Lee

M.C.

, “Synthesis of ¹⁸⁸Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer”, Nucl. Med. Commun. 23, 237 (2002). doi: https://dx-doi-org.web.bisu.edu.cn/10.1097/00006231-200203000-00006

Sundram

Chau

T.C.M.

Onkhuudai

Bernal

Padhy

A.K.

, “Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma”, Eur. J. Nucl. Med. Mol. Imaging 31, 250 (2004). doi: https://dx-doi-org.web.bisu.edu.cn/10.1007/s00259-003-1363-2

10.

Lambert

Bacher

Defreyne

Gemmel

Vlierberghe

H. V.

Jeong

J. M.

Dierckx

R. A.

de Wiele

C. V.

Thierens

De Vos

, “¹⁸⁸Re-HDD/lipiodol therapy for hepatocellular carcinoma: A phase I clinical trial”, J. Nucl. Med. 46, 60 (2005).

11.

Lambert

Bacher

De Keukeleire

Smeets

Colle

Jeong

J.M.

Thierens

Troisi

De Vos

, “¹⁸⁸Re-HDD/lipiodol for treatment of hepatocellular carcinoma: A feasibility study in patients with advanced cirrhosis”, J. Nucl Med. 46, 1326 (2005).

12.

Sundram

F.X.

Jeong

J.M.

Zanzonlco

Divgi

Bernal

Chau

Onkhuudai

Knapp

F.F.

Jr Buscombe

Padhy

A.K.

, “Trans-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma. An IAEA sponsored multi-center phase 1 study”, World J. Nucl. Med. 1, 5 (2002).

13.

Lambert

Bacher

Defreyne

, “Rhenium-188 based radiopharmaceuticals for treatment of liver tumors”, Q. J. Nucl. Med. Mol. Imaging 53, 305 (2009).

14.

Tang

I.C.

Luo

T.Y.

Liu

S.W.

Chan

S.H.

Kung

H.C.

Peng

C.L.

Lin

W.Y.

Chang

Lin

W.J.

, “Synthesis and application of ¹⁸⁸Re-MN-16ET/lipiodol in a hepatocellular carcinoma animal model”, Nucl. Med. Biol. 38, 1043 (2011). doi: https://dx-doi-org.web.bisu.edu.cn/10.1016/j.nucmedbio.2011.03.005

15.

Lin

W.Y.

Luo

T.Y.

Tsai

S.C.

Kao

C.H.

Tang

I.C.

Huang

P.W.

, “A comparison of Re-188-MN-16ET- lipiodol and transcatheter arterial chemoembolization in the treatment of hepatoma: An animal study”, Nucl. Med. Biol. 40, 437 (2013). doi: https://dx-doi-org.web.bisu.edu.cn/10.1016/j.nucmedbio.2012.11.007

16.

Huang

P.W.

Tsai

S.C.

Luo

T.Y.

Kao

C.H.

Lin

W.Y.

, “Therapeutic efficacy of ¹⁸⁸Re-MN-16ET lipiodol in an animal model of hepatocellular carcinoma”, Ann. Nucl. Med. 27, 532 (2013). doi: https://dx-doi-org.web.bisu.edu.cn/10.1007/s12149-013-0717-5

17.

Brandon

E.F.A.

Raap

C.D.

Meijerman

Beijnen

J.H.

Schellens

J.H.M.

, “An update on in vitro test methods in human hepatic drug biotransformation research: Pros and cons”, Toxicol. Appl. Pharmacol. 189, 233 (2003). doi: https://dx-doi-org.web.bisu.edu.cn/10.1016/S0041-008X(03)00128-5

18.

Huang

Liu

Pan

Wang

Tao

Chen

Wang

Peng

Yuan

, “Metabolism of cyadox by the intestinal mucosa microsomes and gut flora of swine, and identification of metabolites by high-performance liquid chromatography combined with ion trap/time-of- flight mass spectrometry”, Rapid Commun. Mass Spectrom. 25, 2333 (2011). doi: https://dx-doi-org.web.bisu.edu.cn/10.1002/rcm.5119

19.

Kaplan

M.M.

Utiger

R.D.

, “Iodothyronine metabolism in rat liver homogenates”, J. Clin. Invest. 61, 459 (1978). doi: http//dx.doi.org/10.1172/JCI108957

20.

Marwah

Lardy

, “Ergosteroids VI. Metabolism of dehydroepiandrosterone by rat liver in vitro: A liquid chromatographic–mass spectrometric study”, J. Chromatogr. B 767, 285 (2002). doi: https://dx-doi-org.web.bisu.edu.cn/10.1016/S1570-0232(01)00570-0

21.

Krebsfaenger

, “Determination of metabolite profile (species comparison) in liver microsomes or hepatocytes”, Available at: http://www.genpharmtox.de/downloads/MetProfAssaySheet.pdf [accessed 14.07.14].